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Reduced cellular immune function in patients after liver transplantation easily results in many types of viral infections, such as 
Epstein-Barr virus. Epstein-Barr virus is a γ-herpesvirus and is related to many malignant diseases, especially epithelial and 
lymph tumors. The abnormal interaction of cluster of differentiation 40 with cluster of differentiation 40 ligand and expression 
of cluster of differentiation 40 ligand are considered closely related to the development of myeloma cells. This study explored 
the influence and mechanism of Epstein-Barr virus infection on the phenotype and biological behavior of myeloma cells after 
liver transplantation. Flow cytometry was used to detect coexpression of cluster of differentiation 40 and cluster of differentia-
tion 40 ligand in 10 samples of freshly isolated multiple myeloma cells. Cluster of differentiation 40 and cluster of differentia-
tion 40 ligand were coexpressed in sample Nos. 5, 8, 9, and 10, particularly in sample No. 5. Western blot analysis was used to 
detect the expression of the Epstein-Barr virus antigens latent membrane protein 1 and Epstein-Barr virus nuclear antigen 2 in 
the multiple myeloma cell line RPMI 8226 infected with Epstein-Barr virus. The antigen expression indicated that Ep-
stein-Barr virus can infect multiple myeloma virus cells in vitro. Reverse transcription-polymerase chain reaction revealed up-
regulated expression of cluster of differentiation 40 ligand on the infected RPMI 8226 cells, which may be involved in the an-
ti-apoptosis activity of the infected cells. Confocal microscopy showed that pairs of molecules of cluster of differentiation 40, 
cluster of differentiation 40 ligand, and latent membrane protein 1 were colocalized on the surface of the infected cells. CXC 
chemokine receptor 4 was upregulated on the RPMI 8226 cells after Epstein-Barr virus infection. The migratory ability of the 
infected cells improved in the presence of the chemokine stromal cell-derived factor-1α. Anti-apoptosis and migration are 
known important biological characteristics of malignant cells. Our results indicate the involvement of Epstein-Barr virus in the 
origin and development of multiple myeloma. The risk of multiple myeloma increases when Epstein-Barr virus infects B cells 
in the germinal center, which may result in an anti-apoptosis effect of B cells and an improved ability to migrate from the ger-
minal center to peripheral blood.  
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After liver transplantation, patients are immunosuppressed [1] 
and become susceptible to all types of infection. A common 
viral infection is caused by Epstein-Barr virus (EBV). The 
clinical presentation of this infection can vary from no 
symptoms to serious fulminant infection [2]. Patients usu-
ally recover spontaneously from the infection, but compli-
cations such as hepatitis, infectious mononucleosis, and 
post-transplant lymphoproliferative disorder can develop. 
Under immunosuppression after liver transplantation, T-cell 
function is suppressed, allowing monoclonicity hyperplasia 
of B cells and tumors to occur [2,3]. 
EBV is a -herpesvirus that is related to many malignant 
diseases, particularly to tumors that are epithelial and lym-
phatic in origin. EBV can infect B cells in vitro and trans-
form them into immortalized lymphoblastoid cell lines. The 
viral antigens expressed by lymphoblastoid cell lines in-
clude the EBV-determined nuclear antigens (EBNA-1 to -6), 
EBV-encoded latent membrane proteins (LMP1 and LMP2), 
and EBV-encoded RNAs [4]. LMP1 plays an important role 
in B-cell transformation. However, B-cell multiplication in 
vitro cannot be maintained by the expression of LMP1 
alone, and a second signal is required [5]. Cluster of differ-
entiation 40 (CD40) is the main accessory of LMP1 signal 
transduction. 
CD40 is a type-I transmembrane glycoprotein that be-
longs to the tumor necrosis factor (TNF) receptor (TNFR) 
superfamily. CD40 is expressed in the different stages of 
B-cell differentiation [6] and in malignant tumor induction 
by B cells, such as in multiple myeloma (MM). CD40 lig-
and (CD40L) is mainly expressed in active CD4+ T cells, 
but was recently also found to be expressed in normal or 
tumor B cells [7,8]. The interaction between abnormal 
CD40 and CD40L proteins enables myeloma cells to sur-
vive [9].  
MM is a malignant tumor that originates from plasma 
cells in the final stage of B-cell differentiation [10]. Tumor 
cell multiplication mostly occurs in the marrow, and tumor 
cells can account for 15%–90% of the total cells. The exact 
etiology of MM is unclear, but it may be related to herpes-
virus infection [11]. Consequently, EBV has received much 
attention in recent years.  
This study was designed to detect the frequency of CD40 
and CD40L coexpression by flow cytometry (FCM) in 
freshly isolated MM cells from 10 post-liver-transplant pa-
tients who developed EBV infection complicated by MM. 
The ex vivo development of EBV infection complicated by 
MM was studied. The ex vivo changes in the phenotypic 
and biological behavior of EBV-infected RPMI 8226 cells 
were also examined, with focus on CD40 and CD40L co-
expression. The aims were to explore the mechanism of the 
malignant transformation of plasma cells into malignant 
MM cells and the effects of EBV infection on MM devel-
opment. 
1  Materials and methods  
1.1  Reagents, cell strains, and bone marrow samples 
CD40 monoclonal antibody (mAb) (5C11, 3G3-FITC), 
CD40L mAb (4F1), LMP1 mAb, EBNA-2 polyclonal anti-
body, and CXC chemokine receptor 4 (CXCR4) mAb were 
purchased from Santa Cruz Biotechnology Co., Ltd., USA. 
Fluorescein isothiocyanate (FITC)-labeled anti-mouse anti-
body was purchased from Immunotech Corporation, France. 
RNA extraction kits and Western blot coloration kits were 
purchased from Shanghai Huashun Corporation, China. 
Reverse transcription-polymerase chain reaction (RT-PCR) 
kits were purchased from Takara Corporation, Japan. An-
nexin-FITC was purchased from Boehringer Mannheim 
Corporation, Germany. Transwell trays were purchased 
from Corning Costar Corporation, Germany. Chemokine 
stromal cell-derived factor-1 (SDF-1) was purchased 
from BD Corporation, USA. Fresh bone marrow samples 
from 10 post-liver-transplant patients with a history of EBV 
infection and MM were obtained from Living Body Liver 
Research Institute, China. The MM cell strain RPMI 8226, 
the cell strain B95-8 from EBV, and the B-cell lymphoma 
cell lines Raji and Daudi were purchased from ATCC Cor-
poration, USA. RPMI 1640 culture medium was purchased 
from GebiCo Corporation, USA. All cell strains were tested 
against mycoplasma contamination using enzyme-linked 
immuno sorbent assay (ELISA) kits from Boehringer 
Mannheim Corporation, Germany. 
Fresh bone marrow samples were obtained from 10 
post-liver-transplant patients who developed EBV infection 
complicated by MM. Diagnosis of MM was performed ac-
cording to internationally recognized criteria (International 
Myeloma Working Group, 2003). There were seven male 
and three female participants. Their ages ranged from 14 
years to 45 years (mean, 27 years). The hepatitis markers 
were 7/3 for B/C, 4/6 for HBV DNA +/, 8/2/0 for 
Child-Pugh grade A/B/C, and 8/2 for alpha fetoprotein +/. 
Preoperative transarterial chemoembolization was per-
formed in one patient. All patients had a single tumor <3 cm 
in size in a single lobe of the liver. The tumor invaded either 
the left or right branch of the portal vein in four patients. 
Serum EBV-IgM was negative in all 10 patients before sur-
gery.  
For immunotherapy, seven patients received cyclosporin 
A and prednisone, whereas three patients received tacroli-
mus and prednisone. All patients were given Stoss therapy 
(100–200 mg methylprednisolone sodium succinate) for 
liver rejection. The patients who were positive for hepatitis 
B surface antigen were treated with lamivudine. Seven pa-
tients developed nonproductive cough, fever, dyspnea, and 
infiltrative lesions upon chest radiography on postoperative 
days 9, 11, 12, 14, 19, and 28. Three patients developed 
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refractory diarrhea, myalgia, arthralgia, nausea, and vomit-
ing on postoperative days 23, 25, and 27, respectively. All 
10 patients had fever, and 4 had increased pharyngeal secre-
tion. Seven patients had enlarged lymph nodes: three in the 
neck and four around the mandible. Two patients had liver 
enlargement, three had spleen enlargement, and four had 
both liver and spleen enlargement. Skin rashes were ob-
served in three patients; bronchitis and bronchopneumonia 
occurred in two. All 10 patients had EBV infection with 
positive serum for EBV-IgM by ELISA. All patients were 
diagnosed with EBV infection and treated accordingly, and 
all eventually recovered. Clinical manifestations of MM 
developed, and MM was diagnosed 9–29 months after liver 
transplantation. Specimens of freshly isolated MM cells 
were obtained from the bone marrow of these patients. In-
formed consent from each patient was obtained according to 
the Declaration of Helsinki as agreed upon by the ethical 
committee of Affiliated Jiangsu Cancer Hospital of Nanjing 
Medical University. 
1.2  FCM analysis of CD40 and CD40L expression in 
MM cells  
Freshly isolated MM cells were collected from the 10 liver 
transplant patients with EBV infection using a standard Fi-
coll-Histopaque procedure. Approximately 3 L each of 
FITC-conjugated CD40 mAb and R-phycoerythrin-conju-     
gated CD40L or CD138 mAb were added to 100 L cell 
suspension (1×106 cells) according to the manufacturer’s 
instructions. After 30 min of incubation at room tempera-
ture in darkness, the stained samples were treated for 10 
min in darkness with 1 mL of Fluorescence Activated Cell 
Sorter (FACS) lysing solution, which was diluted with Mil-
liQ water at a ratio of 1:9. The samples were then washed 
with phosphate buffered saline (PBS) and centrifuged at 
450×g for 5 min at room temperature. The cells were fixed 
in 300 µL of polyformaldehyde solution in darkness for 15 
min at room temperature or overnight at 4C, then washed 
with FACSFlow solution. The cell pellets were resuspended 
in FACSFlow solution and analyzed with a FACScan flow 
cytometer (BD Biosciences, San Jose, CA). 
1.3  Preparation of EBV  
Based on the method of Oh et al. [12], B95-8 cells (5×105 
mL1) in the exponential growth phase were stimulated us-
ing 100 nmol L1 of 12-O-tetradecanoylphorbol-13-acetate 
(TPA) for 2 h. The cells were washed three times with 
HEPES-buffered saline to remove any remaining TPA in 
the solution. After cell culture for 48 h, the supernatant was 
collected by centrifugation at 850×g for 3 min. The super-
natant was passed through a 0.22-m filter and stored in 
1-mL aliquots at 4C in centrifuge tubes. 
1.4  Infection of EBV 
The rate of infection of RPMI 8226 cells increased with 
enriched EBV and prolonged infection time. RPMI 8226 
cells (3×106) in the exponential growth phase were centri-
fuged for 5 min, and the supernatant was discarded after 
each run. Approximately 3 mL of cell suspension contain-
ing the prepared virus was cultured for 16 h. The cells were 
then washed twice with the culture medium to remove the 
virus. A solution of RPMI 1640 containing 10% fetal calf 
serum (FCS) was added to continue the cell culture. A con-
trol group was established using EBV inactivated by ultra-
violet (UV) light (15 W, 60-cm distance, and 60-min irradi-
ation) to infect RPMI 8226 cells.  
1.5  Cell phenotype analysis of antibody immunofluo-
rescence 
At 48 h after the RPMI 8226 cells were infected with EBV, 
immunofluorescence assays were performed. The treatment 
group comprised the EBV-infected cells. The control groups 
included the RPMI 8226 cells cultured in RPMI 1640 with 
10% FCS and without EBV infection or with UV-inactivated 
EBV infection. The cell density of both groups was adjusted 
to 5×106 mL1. Next, 100 L aliquots of the cell cultures 
were incubated with either 1 μg of CD40 mAb (5C11), 1 g 
of CD40L mAb (4F1), or 1 g of LMP1 mAb at 4C for 30 
min. The cells were washed twice with PBS and incubated 
with FITC-labeled anti-mouse antibody at 4C for 30 min. 
After washing again twice with PBS, the cells were sus-
pended in 0.5 mL of PBS and analyzed with FCM. The ex-
periment was repeated three times for each group, and the 
average value was obtained. 
1.6  RT-PCR  
At 24 h after EBV infection, the total number of cells in the 
cultures was adjusted to 5×106 mL1. RPMI 8226 cells with 
UV-inactivated EBV infection were used as a control. Total 
RNA was extracted according to the instructions in the 
RNA extraction kits. After reverse transcription of comple-
mentary DNA, PCR amplification of CD40L was performed 
using a total of 34 cycles (94C for 30 s, 56C for 30 s, and 
72C for 45 s in each cycle). The upstream primer for CD40L 
was 5′-GCCGAATTCGAAAACAGCTTT-3′, whereas the 
downstream primer was 5′-GCCTCTAGAAATCAGAGT- 
TTGAGT-3′ (Immunotech, France). The upstream primer 
for -actin was 5′-TCATGAAGTGTGACGTGGACATC-3′, 
and the downstream primer was 5′-TCTAGTTCTAGTAA- 
CGAGGAGGAC-3′. For the internal standard, 30 cycles of 
-actin amplification were performed as follows: 94C for 
30 s, 53C for 30 s, and 72C for 30 s, with a final extension 
at 72C for 3 min. Electrophoresis was performed with 1% 
sepharose gels to obtain the PCR products. 
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1.7  Western blot analysis 
Approximately 1×106 RPMI 8226 cells from each of the 
two groups were obtained and washed twice with PBS. 
RPMI 8226 cells with UV-inactivated EBV infection were 
used as controls. The cells were resuspended in cold RIPA 
buffer (1× PBS, 1% Nonidet P-40, 0.5% sodium deoxycho-
late, and 0.1% sodium dodecyl sulfate), and then protease 
inhibitor (10 mg mL1 phenylmethanesulfonyl fluoride, 30 
g mL1 Aprotinin, and 100 mmol L1 Na3VO4) was added 
to the suspension. The cells were placed on ice for 30 min, 
aspirated several times with a 1-mL syringe, and centri-
fuged at 1000×g at 4C for 20 min. The supernatant to be 
used for sodium dodecyl sulfatepolyacrylamide gel electro-
phoresis was transferred to a nitric acid fibrous membrane 
and sealed for 1 h with 1% confining liquid. LMP1 mAb or 
EBNA-2 polyclonal antibody was added, and the membrane 
was incubated for 1 h. The unconjugated antibodies were 
washed with Tris-buffered saline with Tween (TBST). After 
adding alkaline phosphatase-labeled goat anti-mouse anti-
body, the membrane was again incubated for 1 h and 
washed three times with TBST. The corresponding substrate 
was added to produce the desired color (details can be found 
in the instructions from BD Corporation, USA). The equiv-
alent protein loading and transfer efficiency were verified 
by staining the membranes for glyceraldehyde-3-phosphate 
dehydrogenase. 
1.8  Cell cycle detection and apoptosis analysis  
Cell cycle detection with propidium iodide (PI) staining: 
The cell concentration of the cultures was adjusted to 5×106 
mL1. From each culture, 100 L cell suspension was col-
lected and mixed with 500 L PI buffer (450 L H2O, 0.05 
mol L1 sodium citrate, 50 g of PI, 0.05% Triton 100, and 
100 g mL1 Rnase) placed at 4C for 30 min in darkness 
and analyzed with FCM.  
Apoptosis analysis: Apoptotic cells were detected using 
PI and Annexin-V by double labeling. Approximately 5×105 
cells were washed twice with PBS and resuspended in 500 
L of cooled PI buffer. To each suspension, 5 L FITC-     
Annexin-V and 5 L PI were added. The suspensions were 
incubated at 4C for 10 min in darkness and then analyzed 
with FCM (details can be found in the instructions from 
Immunotech, France).  
1.9  Detection of cell migration ability toward SDF-1 
Transwell plates with 8-μm pore sizes were divided into 
four groups to detect the ability of the cultured cells to mi-
grate toward the chemokine SDF-1. Group A had cells 
with EBV() RPMI 8226+SDF-1() in RPMI 1640 con-
taining 10% FCS, Group B had EBV(+) RPMI 8226+ 
SDF-1() in RPMI 1640 containing 10% FCS, Group C 
had EBV() RPMI 8226+SDF-1(+) in RPMI 1640 con-
taining 10% FCS, and Group D had EBV(+) RPMI 
8226+SDF-1(+) in RPMI 1640 containing 10% FCS. In 
the upper chamber, approximately 105 cells were added to 
each group. In the lower chamber, 600 L 10% FCS in 
RPMI 1640 containing 200 ng mL1 SDF-1 was added. 
After incubation at 37C for 4 h, the cells were collected 
and counted with FCM to observe the cell migration ability 
in the different groups.  
1.10  Laser confocal microscopy 
Cells at a concentration of 1×105 mL1 were washed with 
PBS, and 100 L of fixation liquid was added to resuspend 
the cells. The suspensions were kept at room temperature 
for 15–30 min. After adding 1 mL PBS/Bull Serum Albu-
min (BSA) (PBS containing 1 mg mL1 BSA), the cells 
were resuspended, centrifuged, and washed twice. The cells 
were then divided into two groups. To one group, 100 μL of 
reaction liquid I (containing 10 g mL1 CD40 polyclonal 
antibody and 10 g mL1 LMP1 mAb in PBS/BSA) was 
added to resuspend the cells, which were kept at room tem-
perature for 30–60 min. Next, 1 mL of PBS/BSA was added 
and the cells were resuspended, centrifuged, and washed 
twice. Thereafter, 100 L reaction liquid II (containing 20 
g mL1 Cy5-goat anti-rabbit IgG and Cy3-goat anti-mouse 
IgG in PBS/BSA) were added, and the cells were resus-
pended, kept at room temperature for 30–45 min, and 
washed. To the other group, 100 L of reaction liquid I 
(containing 10 g mL1 CD40L mAb 4F1 in PBS/BSA) was 
added, and the cells were resuspended and kept at room 
temperature for 30–60 min. Next, 1 mL PBS/BSA was 
added and the cells were resuspended, centrifuged, and 
washed twice. After adding 100 L of reaction liquid II (con-
taining 20 g mL1 Cy3-goat anti-mouse IgG PBS/BSA), the 
cells were resuspended, kept at room temperature for 30–45 
min, and washed. Next, 100 L of reaction liquid III (con-
taining 10 g mL1 3G3-FITC in PBS/BSA) was added and 
the cells were resuspended, kept at room temperature for 
30–45 min, and washed. Both groups of cells were washed 
once, 20 L of covering liquid was added, and the cells 
were resuspended. Approximately 10 L of covering liquid 
containing the cells (prepared as mentioned above) was 
placed on microscope slides, covered with a glass cover slip, 
and observed under a confocal microscope (Bio-Rad). 
1.11  Cell proliferation 
Daudi cells were washed and adjusted to a cell density of 
1×105 mL1 with RPMI 1640 culture medium containing 
10% FCS. Approximately 100 L of cell suspension was 
incubated with IgG and CD40 mAb at concentrations of 0, 5, 
10, and 20 g mL1, respectively, in 96-well plates in an 
 Zhang Y W, et al.   Sci China Life Sci   August (2012) Vol.55 No.8 739 
atmosphere of 5% CO2 at 37C for 24 h. Tritiated thymidine 
of 3.7×104 Bq was then added to each culture well. After 
incubation for 16 h, the cells were harvested to obtain the 
results in cycles per minute results. The experiment was 
carried out in triplicate for each group, and the average re-
sult was obtained. 
1.12  Cell apoptosis  
Four separate groups of Daudi or Raji cells were incubated 
with different treatments: (i) RPMI 1640, (ii) 15 g mL1 
IgG as a homotype control, (iii) 15 g mL1 CD40 mAb, 
and (iv) 15 g mL1 CD40L mAb for 24 h in six-well plates. 
The cells (5×105) were washed three times in PBS and sus-
pended in 500 L of cold PI. Next, 5 L each of FITC-       
Annexin V and PI were added, and the cell suspensions 
were incubated for another 10 min at 4C in darkness. The 
cells were analyzed by FCM.  
1.13  Statistical analysis  
Statistical comparisons were conducted using the Student’s 
t-test, and P<0.05 was considered significant. All statistical 
analyses were carried out with SPSS v11.0 (SPSS Inc., 
Chicago, IL). 
2  Results 
2.1  Coexpression of CD40 and CD40L in freshly iso-
lated MM cells  
CD138 is a labeled molecule of MM. Through the individu-
al detection of CD138 and CD40 or of both CD138 and 
CD40L by double labeling, the expression of CD40 and 
CD40L in MM cells can be determined. The expression of 
CD40 and CD40L differed among the 10 specimens. CD40 
and CD40L were coexpressed in specimen Nos. 5, 8, 9, and 
10 (*, P>0.05) (Figure 1), particularly in specimen No. 5. 
2.2  CD40L surface expression in EBV-infected RPMI 
8226 cells at the RNA and protein levels 
After in vitro cultivation of RPMI 8226 cells and the super-
natant containing EBV, the LMP1 expression in the infected 
cells was detected by immunofluorescence antibody label-
ing and FCM (Figure 2A). The results showed that ap-
proximately 95% of the RPMI 8226 cells were infected with 
EBV. Western blot analysis also detected LMP1 expression 
and EBNA-2 expression in the infected RMPI 8226 cells 
(Figure 3A). RT-PCR analysis performed 24 h after infec-
tion indicated the upregulated expression of CD40L in the 
infected 8226 cells (Figure 3B). FCM performed 48 h after 
infection also indicated the upregulated expression of 
CD40L on the surface of the cell membranes (Figure 2B),  
 
Figure 1  Coexpression of CD40 and CD40L in freshly isolated MM cells 
from 10 liver transplant patients with EBV infection. CD40 and CD40L 
were coexpressed in specimen Nos. 5, 8, 9, and 10 (*, P>0.05), particularly  
in specimen No. 5. 
 
Figure 2  Phenotype detection of EBV-infected RPMI 8226 cells by FCM. 
Surface expression of markers on non-infected cells (light grey area), 
EBV-infected RPMI 8226 cells (dark grey area), or isotype controls 
(dashed line) 48 h after infection. The expression of LMP1, CD40L, and 
CXCR4 on the surface of the cell membranes was upregulated, but the  
expression of CD40 was downregulated. 
 
Figure 3  Biochemistry detection results. A, Western blot analysis of 
LMP1 and EBNA-2 expression 24 h after infection. EBV(0) indicates 
infected RPMI 8226 cells by UV-inactivated EBV, EBV() indicates 
non-infected RPMI 8226 cells, and EBV(+) indicates EBV-infected RPMI 
8226 cells. Upper, LMP1 expression; below, EBNA-2 expression. B, 
RT-PCR detection of CD40L mRNA 24 h after infection. EBV(0) indicates 
infected RPMI 8226 cells by UV-inactivated EBV, EBV() indicates 
non-infected RPMI 8226 cells (constitutive expression of CD40L mRNA), 
and EBV(+) indicates EBV-infected RPMI 8226 cells (upregulation of  
CD40L mRNA). 
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whereas the expression of CD40 was downregulated (Figure 
2C).  
2.3  Anti-apoptosis in EBV-infected RPMI 8226 cells 
No obvious change in the cell cycle of EBV-infected RPMI 
8226 cells was observed 24 h after infection. However, a 
small apoptotic peak appeared before G1 (Figure 4B). At 48 h 
after infection when the upregulated expression of CD40L 
was observed, the apoptotic peak disappeared (Figure 4C). 
The apoptosis ratio of non-infected 8226 cells was 2.35%±     
0.45%. The apoptosis ratio increased to 12.30%±2.10% 24 h 
after infection. When the expression of CD40L was upreg-
ulated 48 h after infection, the apoptosis ratio decreased to 
3.92%±0.42% (Figure 5).  
2.4  CXCR4 expression by the upregulation of EBV- 
infected RPMI 8226 cells 
FCM demonstrated that the RMPI 8226 cells expressed the 
chemokine receptor CXCR4 48 h after infection (Figure 
2D). The infected cells, under the effect of the chemokine 
SDF-1, had a significantly enhanced migration ratio 
(P<0.05) (Figure 6). 
2.5  Colocation of CD40, CD40L, and LMP1 on infected 
cells 
FCM showed green fluorescence with direct immunofluo-
rescence antibody 3G3-FITC, which labeled the CD40 
molecule on the surface of the infected cells. FCM showed 
red fluorescence with indirect immunofluorescence anti-
body 4F1 or with anti-LMP1 that labeled CD40L when 
combined with a secondary antibody Cy3. FCM showed 
yellow fluorescence if the two molecules CD40 and CD40L 
colocated on the surface of the infected cells. Confocal mi-
croscopy showed that the RPMI 8226 cells became irregular 
after infection and that CD40 and CD40L, or EBV protein 
LMP1, can colocalize on the cell surface (yellow fluores-
cence) (Figure 7). Thus, LMP1 may be involved in CD40 
signal transduction.  
2.6  Effects of CD40-CD40L on Daudi cell proliferation  
Daudi cell proliferation was examined after treatment with 
homotype IgG (the control group), CD40 mAb, or CD40L  
 
 
Figure 4  Cell cycle stages of EBV-infected RPMI 8226 cells with PI staining followed by flow cytometry analysis. The arrow indicates sub-G1 24 h after 
infection, which disappeared 48 h after infection when CD40L was up-regulated. 
 
Figure 5  Apoptosis ratio of RPMI 8226 cells after EBV infection. The 
apoptosis index of non-infected RPMI 8226 cells was 2.35%±0.45% (0 h). 
The apoptosis index of EBV-infected RPMI 8226 cells 24 h after infection 
was 12.30%±2.10% (24 h) (P<0.05 vs. other groups). The apoptosis index 
of EBV-infected RPMI 8226 cells was 3.92%±0.42% 48 h after infection  
when CD40L was upregulated. 
 
 
Figure 6  Migration ability of EBV-infected RPMI 8226 cells toward 
SDF-1. In the absence of SDF-1, 4.79%±0.52% of the non-infected 
RPMI 8226 cells migrated, whereas 4.14%±0.31% of the EBV-infected 
RPMI 8226 cells migrated. In the presence of SDF-1, 10.04%±1.03% of 
the non-infected RPMI 8226 cells migrated, whereas 13.18%±1.21% of the 
EBV-infected RPMI 8226 cells migrated. *, P<0.05 vs. infected RPMI  
8226 cell migration in the absence of SDF-1. 
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mAb. The results showed that both CD40 and CD40L mAbs 
inhibited Daudi proliferation in a dose-dependent manner. 
The inhibition of CD40L mAb was stronger than that of 
CD40 mAb (Figure 8).  
2.7  Effects of CD40-CD40L on Raji cell apoptosis 
Apoptosis was examined after treatment with homotype IgG 
(control group), CD40 mAb, or CD40L mAb. The results 
showed that both CD40 and CD40L mAbs increased the 
rate of Raji cell apoptosis. However, only CD40L mAb in-
creased the rate of Daudi cell apoptosis. CD40 mAb had no 
significant effect on Daudi cell apoptosis (Figure 8). 
3  Discussion 
CD40, a 45- to 50-kD membrane, belongs to the TNFR su-
perfamily. CD40 is mainly expressed on mature B cells and 
may be involved in a variety of biological effects. In many  
 
 
Figure 7  Colocalization of a pair of molecules of CD40, CD40L, and 
LMP1 on infected RPMI 8226 cells using confocal microscopy. 
CD40/CD40L and LMP1/CD40 are colocalized on the cell surface (yellow  
fluorescence). 
 
Figure 8  Apoptosis ratio of Daudi or Raji cells with different treatments. 
1, RPMI 1640 medium; 2, 15 g mL1 IgG as homotype control; 3, 15 ug 
mL1 CD40 mAb; 4, 15 g mL1 CD40L mAb for 24 h in six-well plates. 
Both CD40 and CD40L mAbs increased the rate of Raji cell apoptosis. 
However, only CD40L mAb increased the rate of Daudi cell apoptosis.  
CD40 mAb had no significant effect on Daudi cell apoptosis. 
ways, CD40 is similar to LMP1, a viral protein expressed 
on B cells that have been transformed by EBV. During 
CD40 ligation, CD40 and LMP1 on the transformed cells 
can be recruited to lipid rafts to create a signal transduction 
complex. CD40L, the ligand of CD40, also known as 
CD154, is a 39-kD membrane molecule from the TNF su-
perfamily. CD40L is transiently expressed on the germinal 
center (GC) of B cells or abnormally expressed on 
B-cell-originated malignant cells. The maturation of B cells 
is known to depend on their binding to CD40L, which is 
transiently expressed on CD40+ T cells within the GC. This 
binding promotes the ligation of CD40 on B cells and re-
sults in the survival, proliferation, and differentiation of the 
high-affinity, non-autoreactive B cells. The CD40-CD40L 
interaction between the B and T cells within the GC is able 
to prevent the apoptosis of B cells. However, the number of 
T cells within the GC is limited, and the expression of 
CD40L on the B cells in the GC is transient. This strict se-
lection leads to the survival of only a fraction of the func-
tional B cells, whereas the majority of malignant or autore-
active B cells that fail to bind to T cells are destroyed. Un-
fortunately, many malignant cells can still escape this selec-
tive process within the GC, survive, and proliferate. Recent 
research has shown that receptors and ligands can be coex-
pressed in the same cells, particularly in malignant cells 
[13]. Some carcinogenic factors such as viral infection can 
result in ectopic or upregulated expression, which conse-
quently allows malignant cells to avoid apoptosis or the 
attack of immune cells. The exact effects of the coexpres-
sion of receptors and ligands on malignant cells warrant 
further research.  
The abnormal expression of both CD40 and CD40L on 
B-cell-originated malignant cells is involved in the devel-
opment of tumors. The interaction of CD40 and CD40L is 
used in cell transformation in many carcinogens, such as in 
viral infections [14]. Whether the CD40L provided by these 
cells or the upregulation of CD40L enables the survival of 
malignant B cells, which normally cannot enter the T-cell-      
dependent pathway in the GC, remains unclear. Studies on 
CD40-CD40L interactions in tumors, as well as the changes 
in their expression and their biological effects under special 
conditions such as viral infections, provide important in-
formation for research on tumor development. 
The present study showed that EBV can cause ex vivo 
infection of RPMI 8226 cells. FCM and Western blot anal-
ysis detected the expression of LMP1 and EBVA-2 at the 
protein level. FCM and RT-PCR detected the upregulated 
expression of CD40L after EBV infection. Other research-
ers reported that LMP1 plays a key role in B-cell transfor-
mation by EBV [15,16]. Although LMP1 is very similar to 
CD40 in terms of the signal transduction pathway and in the 
recruitment of TNF receptor-associated factor signaling 
molecules, it cannot entirely replace CD40 [17] because 
LMP1 and CD40 differ in some aspects. After a cell re-
ceives CD40L aglycone, LMP1 and CD40 can colocalize 
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and form a signal transduction complex in the form of a 
lipid raft that transmits the signal to the target cell [18]. 
B-cell proliferation in vitro cannot be maintained by the 
expression of LMP1 alone. Thus, both CD40 and CD40L 
may be required for this process.  
FCM, RT-PCR, and Western blot analysis demonstrated 
the slight expression of CD40L in RPMI 8226 cells. This 
finding is consistent with that of a published report that 
showed CD40 and CD40L coexpression in B lymphomas 
[19].  
The expression of CD40L was upregulated by EBV-  
infected B cells [20,21]. These CD40L molecules played an 
important part in the course of the transformation of B cells 
into immortalized lymphoblastoid cell lines. The upregu-
lated expression of CD40L in RPMI 8226 cells may be re-
lated to the resistance of the infected cells to apoptosis [22]. 
Cell cycle analysis revealed an apoptotic peak of the cells 
24 h after infection with a large dose of the virus. When 
CD40L was upregulated 48 h after infection, the apoptotic 
peak disappeared (Figure 4C). A similar result was found by 
double labeling with Annexin-V and PI to detect apoptosis 
(Figure 5). However, CD40 was downregulated after infec-
tion (Figure 2C). A previous report showed that CD40 in-
duced the production of interleukin-10 at a low dose and 
induced the secretion of interleukin-12 at a high dose [23]. 
Our previous research also showed that CD40 antibody 
stimulated MM cell proliferation at a low dose but induced 
the apoptosis of myeloma cells at a high dose [24,25]. 
Therefore, the infected cells may be regulated through 
CD40L upregulation and CD40 downregulation such that a 
favorable signal intensity is reached to regulate cell growth.  
Malignant transformation of tumor cells changes some 
normal physiological activities [26]. In the present study, 
the abnormal expression of CD40L, the coexpression of 
CD40 and CD40L, and their colocalization on the surface of 
the B lymphoma cell lines Daudi and Raji were all observed. 
CD40 or CD40L mAb prevented CD40-CD40L signal 
transduction in two ways. These antibodies can destroy the 
signal transduction complex on the surface of individual 
cells. Alternatively, the antibodies prevent the intracellular 
signal transduction of CD40 and CD40L, thereby inhibiting 
tumor cell survival and proliferation and the increased rate 
of apoptosis. When an inhibitory effect becomes predomi-
nant, the signal transduction complex is destroyed and the 
signal transduction is stopped at the level of a single mole-
cule of the complex. Thus, the CD40 signal transduction 
complex can be used as a target for the clinical therapy of 
tumors.  
In conclusion, the upregulated expression of CD40L on 
EBV-infected MM cells from liver transplant patients are 
involved in the transformation of plasma cells into MM cells. 
The mechanism is similar to the persistent and high-intensity 
expression of CD40L in the GC, which enables cells to un-
dergo apoptosis. The expression of the chemokine receptor 
CXCR4 is upregulated after infection (Figure 2D) and cell 
migration is significantly promoted, with an increase in the 
migratory ability of the cells. The findings of this study on 
the relationship between EBV-induced diseases and the 
CD40-CD40L interaction require confirmation.  
The upregulated expression of CD40L on EBV-infected 
MM cells after liver transplantation influences plasma cell 
transformation to MM and the anti-apoptosis effect of MM 
cells after infection. CD40 and CD40L or the EBV antigen 
LMP1 are colocalized on the surface of EBV-infected cells. 
These membrane proteins are also coexpressed and colocal-
ized on freshly isolated MM cells and on the B lymphoma 
cell lines Daudi and Raji. 
The coexpression of CD40 and CD40L is significant be-
cause when CD40-CD40L signal transduction is inhibited 
by CD40 or CD40L mAb, Daudi or Raji cell growth, prolif-
eration, and induction of cell apoptosis are remarkably in-
hibited. These inhibitory effects can be adjusted using dif-
ferent antibodies on the different molecules, and the effects 
of these antibodies are dose-dependent.  
The relationship between EBV-induced diseases and the 
CD40-CD40L interaction should be further studied to dis-
cover a new approach to the prevention of myelomas 
through immunotherapy. 
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